Boehringer Ingelheim Venture Fund
Corporate VCIngelheim am Rhein · Seed–Growth
Investment thesis
Boehringer Ingelheim Venture Fund, established in 2010, invests in biotechnology companies developing therapeutics in immuno-oncology, regenerative medicine, and gene therapy, including platform technologies and novel vaccines. The fund targets early-stage companies addressing unmet medical needs through translational research and scientific innovation.
Source: firm website, verified Jul 31, 2026.
What they invest in
from 2 of 2 portfolio companiesBiotech ×2Deep Tech ×2Healthtech ×2Digital Health ×1
HQs:Belgium×1France×1
Investments · 2 tracked
founders shown can be your intro pathDiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.
BiotechDeep TechDigital HealthHealthtechMarseille, FR
Benjamin Charles(Co-Founder & CEO)Patrick Collombat(Co-Founder & Scientific Advisor)Jean-Pascal Tranié(Co-Founder)
Frequently asked questions
- What stage does Boehringer Ingelheim Venture Fund invest at?
- Boehringer Ingelheim Venture Fund invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Boehringer Ingelheim Venture Fund's typical check size?
- Boehringer Ingelheim Venture Fund typically writes checks of $16.2M.
- What sectors does Boehringer Ingelheim Venture Fund focus on?
- Boehringer Ingelheim Venture Fund focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Boehringer Ingelheim Venture Fund located?
- Boehringer Ingelheim Venture Fund is headquartered in Ingelheim am Rhein, DE.
Co-investors · 6
The JDRF T1D Fund is a venture philanthropy investor focused on type 1 diabetes (T1D), backing companies developing disease-modifying therapies and cures for the condition.
Insight Partners is a venture and growth-stage software investor featuring a large portfolio of technology companies across multiple sectors and regions.
Playground Global is a venture firm focused on deep technology, working alongside founders as engineers, operators, and scientists to help commercialize breakthrough technology into scalable businesses.
Distributed Ventures is an early-stage venture firm that leads Seed and Series A investments in companies innovating across the health, insurance, and wealth risk ecosystems.
Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.
Esplanade Ventures is a Canadian venture capital firm focused on early-stage digital health technology companies transforming care in the U.S. and Canada.
Firms observed investing alongside Boehringer Ingelheim Venture Fund, from public investor directories. Shared companies are the overlap with Boehringer Ingelheim Venture Fund's recorded portfolio.
Similar investors
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
OneVentures is a later-stage venture capital firm that backs technology and healthcare companies, providing growth equity and credit alongside strategic and operational support.
Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.